Analystreport

Dermira, Inc. (NASDAQ: DERM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $46.00 price target on the stock.

Journey Medical Corporation  (DERM) 
Last journey medical corporation earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.dermira.com